PDE6C

Across TCGA pan-cancer cohorts, PDE6C RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of PDE6C’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PDE6C RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PDE6C is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

LIHC, KIRC, and CHOL are the cancer types where PDE6C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDE6C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.176	<.001	8	view →
KIRC	Female	All	+0.141	<.001	8	view →
CHOL	All	All	+0.704	.003	5	view →
BRCA	All	III,IV	−0.134	.027	4	view →
BLCA	Female	All	+0.207	.024	2	view →
LUSC	Female	III,IV	−0.104	.036	2	view →
LUAD	Female	II,III,IV	−0.154	.049	1	view →
STAD	Male	II,III,IV	+0.120	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

PDE6C–LIHC

Open the LIHC breakdown →